Physician
Oncology
Dr. Henry Q. Xiong, MD
|
|
Give Review
Henry Q. Xiong, MD practices Oncology. He went to Shanghai Medical University. He received 1 awards: "Physician Practice Connections Recognition Program". Dr. Henry Q. Xiong has written publications. He has 37 publications published with PubMed. The lastest publication is: 'Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial.' Henry Xiong is registered with Medicare and accepts Medicare payments.
Publications
- Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic Cancer.
- Patterns of self-reported symptoms in pancreatic Cancer patients receiving chemoradiation.
- Borderline resectable pancreatic Cancer: definitions, management, and role of preoperative therapy.
- Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell Carcinoma.
- Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic coloRectal metastases.
- Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human panc...
- Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic Cancer.
- Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic Cancer cells.
- Pharmacodynamic Analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or S...
- A phase I surrogate endpoint study of SU6668 in patients with solid Tumors.
- Adjuvant therapy for pancreatic Cancer: current status and future directions.
- Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic Cancer: a multicenter phase II...
- Novel therapies for pancreatic adenoCarcinoma.
- Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic Cancer via suppression of Sp1 transcrip...
- NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic Cancer cells.
- Treatment of coloRectal cancer metastasis: the role of chemotherapy.
- Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid Tumors.
- Experimental animal models of pancreatic carcinogenesis and metastasis.
- Epidermal growth factor receptor-targeted therapy for pancreatic Cancer.
- An Analysis of the current status of hospital emergency preparedness for infectious disease outbreaks in Beijing, China.
- Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenoCarcinoma of the pancreatic head.
- Yttrium 90 resin microspheres for the treatment of unresectable coloRectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results.
- Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid Tumors.
- Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic Cancer cells.
- Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic Cancer: a phase II trial.
- Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic Cancer: results of two phase II studies.
- Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid Tumors.
- Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic Tumor xenografts.
- Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic coloRectal cancer.
- Molecular targeting therapy for pancreatic Cancer.
- Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic Cancer angiogenesis and metastasis.
- Chemoradiation for resectable gastric Cancer.
- Report of the 16th International Symposium of the Foundation for Promotion of Cancer Research: Recent advances in pancreatic Cancer.
- Radiation dose considerations in the palliative treatment of locally advanced adenoCarcinoma of the pancreas.
- A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic Cancer.
- Cytotoxic chemotherapy for pancreatic Cancer: Advances to date and future directions.
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
- Aetna
- Blue Cross Blue Shield
- Great West Healthcare-Cigna
- Cigna-HealthSpring
- Coventry Health Care
- First Health (Coventry Health Care)
- HealthSmart
- Choice
- Special Needs Plan SNP
- MultiPlan
- PHCS
- Teachers Retirement System (TRS)
- TriCare for Life
- Secure Horizons
- United Healthcare
Awards
- Physician Practice Connections Recognition Program
Education
-
University of Texas Health Science Center -
Mount Sinai Beth Israel -
Shanghai Medical University
Hospital
-
Baylor All Saints Medical Center at Fort Worth -
Texas Health Harris Methodist Hospital Fort Worth -
Texas Health Huguley Hospital Fort Worth South -
Plaza Medical Center of Fort Worth -
Medical Center Arlington
Drug Facts
| NPI NUMBER | 1518910561 | |
| NPPES Provider LastName | XIONG | |
| NPPES Provider FirstName | HENRY | |
| NPPES Provider ZIPCode | 761044611 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1319.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 350.0 | |
| Percent Opioid Claims | 26.54 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1518910561 |
| Last Name Of The Provider | XIONG |
| First Name Of The Provider | HENRY |
| View All |
Similar Doctors
|
Dr. Asad Dean, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard A. Artim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen L. Richey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William M. Jordan, DO |
|
|
Dr. Angel G. Negron, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chi M. Pham, MD |
|
|
Dr. Bibas Reddy, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anuradha Lingam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert L. Ruxer Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory P. Cusano, DO |
|
|
Dr. Harold L. Mandell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen H. Albritton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Latha S. Neerukonda, MD
This Doctor is OpenDoctor Recommended.
|